John Radford is Professor of Medical Oncology at the University of Manchester. He is widely recognised as being at the forefront of patient orientated research in lymphatic cancer through a series of important practice changing studies and innovations. He has made a major contribution in the field of post-treatment surveillance and management of late toxicity. He has remodelled long-term follow-up in the ADAPT project, funded by NHS Commissioners, and designed and leads the breast screening after radiotherapy dataset project (BARD). This was described by the National Screening Director as “a model for the surveillance of clinically identified high risk populations”.